Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
Summary
The extension round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. Since its launch in June 2023, VisionSort has been adopted by major biopharmaceutical companies and leading academic institutions worldwide.The new funding will drive production and manufacturing scale-up as well as help accelerate global commercial expansion. With this stable footing, ThinkCyte is poised to broaden the impact of its technologies, driving advancements in the life sciences and maintaining its leadership in innovative single-cell analysis and sorting solutions.ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The companys flagship product, VisionSort, is the worlds first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit www.thinkcyte.com.To learn more about research partnerships or other partnering opportunities with ThinkCyte, contact us.
Funding
Review available funding amount, funding date, investors, and linked company information related to Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™ in the interactive ISVWorld profile.